Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbidity and mortality

Expert Review of Vaccines

Volumn 11, Issue 2, 2012, Pages 211-220

  Tate, Jacqueline E ^a   Patel, Manish M ^a   Cortese, Margaret M ^a   Lopman, Benjamin A ^a   Gentsch, Jon R ^a   Fleming, Jessica ^b   Steele, A Duncan ^b   Parashar, Umesh D ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b PATH   (United States)

Author keywords

diarrhea; rotavirus; rotavirus vaccine

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE;

CHILDHOOD DISEASE; DEVELOPING COUNTRY; DIARRHEA; DRUG MONITORING; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INTUSSUSCEPTION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; VACCINATION;

CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DEVELOPING COUNTRIES; DIARRHEA; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MORBIDITY; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; WORLD HEALTH;

EID: 84856935991     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.184     Document Type: Review

References (82)

1. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med. 354(1), 11-22 (2006). (Pubitemid 43048947)
2. Vesikari T, Matson DO, Dennehy P et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 354(1), 23-33 (2006). (Pubitemid 43048948)
3. Conclusions and recommendations from the Immunization Strategic Advisory Group. Wkly Epidemiol. Rec. 81(1), 2-11 (2006).
4. Meeting of the Immunization Strategic Advisory Group of Experts, April 2009 - conclusions and recommendations. Wkly Epidemiol. Rec. 84(23), 220-236 (2009).
5. Rotavirus vaccines: An update. Wkly Epidemiol. Rec. 84(50), 533-540 (2009).
6. Meeting of the Strategic Advisory Group of Experts on immunization, October 2009 - conclusions and recommendations. Wkly Epidemiol. Rec. 84(50), 517-532 (2009).
7. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect. Dis. doi:10.1016/S1473- 3099(11) 70253-5 (2011) (Epub ahead of print).
8. Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg. Infect. Dis. 12(2), 304-306 (2006).
9. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N. Engl. J. Med. 362(4), 299-305 (2010).
10. Richardson V, Parashar U, Patel M. Childhood diarrhea deaths after rotavirus vaccination in Mexico. N. Engl. J. Med. 365(8), 772-773 (2011).
11. do Carmo GM, Yen C, Cortes J et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: A time-series analysis. PLoS Med. 8(4), e1001024 (2011).
12. Yen C, Armero Guardado JA, Alberto P et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr. Infect. Dis. J. 30(Suppl. 1), S6-S10 (2011).
13. Quintanar-Solares M, Yen C, Richardson V, Esparza-Aguilar M, Parashar UD, Patel MM. Impact of rotavirus vaccination on diarrhea-related hospitalizations among children
14. Molto Y.Cortes J.E.De Oliveira L.H.et al. Reduction of Diarrhea-Associated Hospitalizations Among Children Aged
15. Paulke-Korinek M, Rendi-Wagner P, Kundi M, Kronik R, Kollaritsch H. Universal mass vaccination against rotavirus gastroenteritis: Impact on hospitalization rates in Austrian children. Pediatr. Infect Dis. J. 29(4), 319-323 (2010).
16. Paulke-Korinek M, Kundi M, Rendi- Wagner P et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 29(15), 2791-2796 (2011).
17. Field EJ, Vally H, Grimwood K, Lambert SB. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 126(3), e506-e512 (2010).
18. Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: Analysis of hospital discharge data from 18 US states. J. Infect. Dis. 201(11), 1617-1624 (2010).
19. Cortese MM, Tate JE, Simonsen L, Edelman L, Parashar UD. Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases. Pediatr. Infect. Dis. J. 29(6), 489-494 (2010).
20. Yen C, Tate JE, Wenk JD, Harris JM 2nd, Parashar UD. Diarrhea-associated hospitalizations among US children over 2 rotavirus seasons after vaccine introduction. Pediatrics 127(1), e9-e15 (2011).
21. Rotavirus surveillance - worldwide, 2009. MMWR Morb. Mortal. Wkly Rep. 60(16), 514-516 (2011).
22. Steele AD, Reynders J, Scholtz F et al. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. J. Infect. Dis. 202(Suppl.) S93-S100 (2010).
23. Madhi SA, Cunliffe NA, Steele D et al. Effect of human rotavirus vaccine on severediarrhea in African infants. N. Engl. J. Med. 362(4), 289-298 (2010).
24. Vesikari T, Karvonen A, Prymula R et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: Randomised, double-blind controlled study. Lancet 370(9601), 1757-1763 (2007). (Pubitemid 350137490)
25. Armah GE, Sow SO, Breiman RF et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: A randomised, double-blind, placebo-controlled trial. Lancet 376(9741), 606-614 (2010).
26. Zaman K, Dang DA, Victor JC et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: A randomised, double-blind, placebocontrolled trial. Lancet 376(9741), 615-623
27. Vesikari T, Karvonen A, Ferrante SA, Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: The Finnish Extension Study. Eur. J. Pediatr. 169(11), 1379-1386 (2010).
28. Patel M, Pedreira C, De Oliveira LH et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 301(21), 2243-2251 (2009).
29. Mast TC, Khawaja S, Espinoza F et al. Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua. Pediatr. Infect. Dis. J. 30(11), e209-e215 (2011).
30. Generic protocol for monitoring impact of rotavirus vaccination on gastroenteritis disease burden and viral strains. World Health Organization, Geneva, Switzerland (2008).
31. Hanlon P, Hanlon L, Marsh V et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1(8546), 1342-1345 (1987). (Pubitemid 17076248)
32. De Mol P, Zissis G, Butzler JP, Mutwewingabo A, Andre FE. Failure of live, attenuated oral rotavirus vaccine. Lancet 2(8498), 108 (1986). (Pubitemid 16097112)
33. Lanata CF, Black RE, del Aguila R et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J. Infect. Dis. 159(3), 452-459 (1989). (Pubitemid 19065891)
34. Georges-Courbot MC, Monges J, Siopathis MR et al. Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in central Africa. Res. Virol. 142(5), 405-411 (1991).
35. John TJ. Antibody response of infants in tropics to five doses of oral polio vaccine. BMJ 1(6013), 812 (1976).
36. John TJ, Jayabal P. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am. J. Epidemiol. 96(4), 263-269 (1972).
37. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review. Rev. Infect. Dis. 13(5), 926-939 (1991).
38. Suharyono, Simanjuntak C, Witham N et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 340(8821), 689-694 (1992).
39. Gotuzzo E, Butron B, Seas C et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun. 61(9), 3994-3997 (1993). (Pubitemid 23260079)
40. Linhares AC, Gabbay YB, Mascarenhas JD et al. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull. World Health Organ. 74(5), 491-500 (1996). (Pubitemid 27015917)
41. Steele AD, De Vos B, Tumbo J et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 28(39), 6542-6548 (2008).
42. Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 13(3), 310-312 (1995).
43. Albert MJ, Qadri F, Wahed MA et al. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. J. Infect. Dis. 187(6), 909-913 (2003). (Pubitemid 36337903)
44. Ahmed T, Svennerholm AM, Al Tarique A, Sultana GN, Qadri F. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine 27(9), 1433-1439 (2009).
45. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines: how well will they work where they are needed most? J. Infect. Dis. 200(Suppl. 1), S39-S48 (2009).
46. Moon SS, Wang Y, Shane AL et al. Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr. Infect. Dis. J. 29(10), 919-923 (2010).
47. Rennels MB. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. J. Infect. Dis. 174(Suppl. 1), S107-S111 (1996). (Pubitemid 26293130)
48. Dennehy PH, Brady RC, Halperin SA et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr. Infect. Dis. J. 24(6), 481-488 (2005). (Pubitemid 40847519)
49. Goveia MG, DiNubile MJ, Dallas MJ,Heaton PM, Kuter BJ. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatr. Infect. Dis. J. 27(7), 656-658 (2008).
50. Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr. Infect. Dis. J. 29(10), 957-963 (2010).
51. Boom JA, Tate JE, Sahni LC et al.Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. Pediatr. Infect. Dis. J. 29(12), 1133-1135 (2010).
52. Correia JB, Patel MM, Nakagomi O et al. Effectiveness of monovalent rotavirusvaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J. Infect. Dis. 201(3), 363-369 (2010).
53. de Palma O, Cruz L, Ramos H et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: Case-control study. BMJ 340, c2825 (2010).
54. Justino MC, Linhares AC, Lanzieri TM et al. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belem, Brazil. Pediatr. Infect. Dis. J. 30(5), 396-401 (2011).
55. Snelling TL, Andrews RM, Kirkwood CD, Culvenor S, Carapetis JR. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin. Infect. Dis. 52(2), 191-199 (2011).
56. Murphy TV, Gargiullo PM, Massoudi MS et al. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. 344(8), 564-572 (2001). (Pubitemid 32167870)
57. Withdrawal of rotavirus vaccine recommendation. MMWR Morb. Mortal. Wkly Rep. 48(43), 1007 (1999).
58. Peter G, Myers MG. Intussusception, rotavirus, and oral vaccines: Summary of a workshop. Pediatrics 110(6), e67 (2002).
59. Patel MM, Lopez-Collada VR, Bulhoes MM et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N. Engl. J. Med. 364(24), 2283-2292 (2011).
60. Buttery JP, Danchin MH, Lee KJ et al. Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia. Vaccine 29(16), 3061-3066 (2011).
61. Belongia EA, Irving SA, Shui IM et al. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr. Infect. Dis. J. 29(1), 1-5 (2010).
62. Haber P, Patel M, Izurieta HS et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 121(6), 1206-1212 (2008).
63. Cortese M. Estimates of benefits and potential risks of rotavirus vaccination in the U.S. Presented at: Advisory Committee on Immunization Practices Meeting. Atlanta, GA, USA, 27-28 October 2010.
64. Meeting of the Global Advisory Committee on Vaccine Safety, December 2010. Wkly Epidemiol. Rec. 86(5), 38-43 (2011).
65. Bines JE, Liem NT, Justice F et al. Validation of clinical case definition of acute intussusception in infants in Viet Nam and Australia. Bull. World Health Organ. 84(7), 569-575 (2006). (Pubitemid 44186355)
66. Staat MA, Payne DC, Donauer S et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics 128(2), e267-e275 (2011).
67. Yen C, Figueroa JR, Uribe ES et al. Monovalent rotavirus vaccine provides protection against an emerging fully heterotypic G9P[4] rotavirus strain in Mexico. J. Infect. Dis. 204(5), 783-786 (2011).
68. Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009. Wkly Epidemiol. Rec. 84(32), 325-332 (2009).
69. Patel MM, Clark AD, Glass RI et al. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception. Vaccine 27(22), 2916-2922 (2009).
70. Bhan MK, Lew JF, Sazawal S, Das BK, Gentsch JR, Glass RI. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J. Infect. Dis. 168(2), 282-287 (1993). (Pubitemid 23210600)
71. Das BK, Gentsch JR, Hoshino Y et al. Characterization of the G serotype and genogroup of New Delhi newborn rotavirus strain 116E. Virology 197(1), 99-107 (1993).
72. Glass RI, Bhan MK, Ray P et al. Development of candidate rotavirus vaccines derived from neonatal strains in India. J. Infect. Dis. 192(Suppl. 1), S30-S35 (2005). (Pubitemid 41193099)
73. Vethanayagam RR, Ananda Babu M, Nagalaxmi KS et al. Possible role of neonatal infection with the asymptomatic reassortant rotavirus (RV) strain I321 in the decrease in hospital admissions for RV diarrhea, Bangalore, India, 1988-1999. J. Infect. Dis. 189(12), 2282-2289 (2004). (Pubitemid 38757201)
74. Rippinger CM, Patton JT, McDonald SM. Complete genome sequence analysis of candidate human rotavirus vaccine strains RV3 and 116E. Virology 405(1), 201-213 (2010).
75. Bhandari N, Sharma P, Taneja S et al. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirusvaccine 116E in infants: A randomized, double-blind, placebo-controlled trial. J. Infect. Dis. 200(3), 421-429 (2009).
76. Barnes GL, Lund JS, Adams L et al. Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate. J. Paediatr. Child Health 33(4), 300-304 (1997). (Pubitemid 27396182)
77. Barnes GL, Lund JS, Mitchell SV et al. Early Phase 2 trial of human rotavirus vaccine candidate RV3. Vaccine 20(23-24), 2950-2956 (2002). (Pubitemid 34785966)
78. Kapikian AZ, Simonsen L, Vesikari T et al. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J. Infect. Dis. 192(Suppl. 1), S22-29 (2005). (Pubitemid 41193098)
79. Clements-Mann ML, Makhene MK, Mrukowicz J et al. Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine 17(20-21), 2715-2725 (1999). (Pubitemid 29314469)
80. Vesikari T, Karvonen AV, Majuri J et al. Safety, efficacy, and immunogenicity of two dose of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J. Infect. Dis. 194(3), 370-376 (2006). (Pubitemid 44116980)
81. Global Advisory Committee on Vaccine Safety, 1-2 December 2005. Wkly Epidemiol. Rec. 81(2), 15-19 (2006).
82. Jiang B, Gentsch JR, Glass RI. Inactivated rotavirus vaccines: A priority for accelerated vaccine development. Vaccine 26(52), 6754-6758 (2008).